Study on the synergistic effects of aspirin and atorvastatin on cell proliferation of non-small cell lung cancer cells
10.12206/j.issn.1006-0111.202003191
- VernacularTitle:阿司匹林联合阿托伐他汀协同抑制非小细胞肺癌细胞增殖及其机制研究
- Author:
Jun YU
1
;
Jingjing DUAN
1
;
Ye ZHANG
1
Author Information
1. Department of Pharmacy, Shanghai fengxian Central Hospital, Shanghai 201499，China.
- Keywords:
aspirin;
atorvastatin;
synergistic effect;
non-small cell lung cancer;
mTOR and NFκB signaling pathway
- From:
Journal of Pharmaceutical Practice
2021;39(1):38-43
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the synergistic effects of aspirin and atorvastatin on cell proliferation of non-small cell lung cancer cell A549 and NCI-H460 and the mechanism of these actions. Methods The proliferation of A549 and NCI-H460 cells treated by aspirin or/and atorvastatin were determined by MTS assay. The migration of A549 and NCI-H460 cells were conducted by wound-healing assay. The expression of relevant protein in mTOR and NFκB signaling pathway were detected by western blotting. The mRNA expression of TNF-α and IL-1β were detected by quantitative real-time PCR. Results Aspirin or/and atorvastatin inhibited the proliferation and migration of A549 and NCI-H460 at concentration of 100 and 5 μmol/L or greater. The effect was enhanced by the combination of aspirin and atorvastatin. Aspirin or/and atorvastatin inhibited the protein expression of the phosphorylation of mTOR and NFκB, and down-regulated anti-apoptotic regulators Bcl-2 and Mcl-1 in NCI-H460 cells. The combination treatment of aspirin and atorvastatin was more efficacious than the single treatment. Atorvastatin decreased the mRNA expression of TNF-α. The combination of atorvastatin with aspirin decreased the mRNA expression of IL-1β by nearly 50 percent compared to the control (P<0.05). Conclusion Aspirin and atorvastatin have synergistic inhibitory effects on cell growth of non-small cell lung cancer cell A549 and NCI-H460 by suppressing mTOR and NFκB signaling pathway.
